{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:20:33Z","timestamp":1789118433203,"version":"build-2803163510"},"reference-count":146,"publisher":"Open Exploration Publishing","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Explor Target Antitumor Ther"],"accepted":{"date-parts":[[2026,7,24]]},"abstract":"<jats:p xml:lang=\"en\">Endocrine treatment in combination with CDK4\/6 inhibitors represents the mainstay of first-line palliative treatment in HR+\/HER2\u2013 breast cancer. The treatment landscape after progression on CDK4\/6 inhibitors has evolved into a complex and rapidly evolving field, driven by novel endocrine and targeted agents, new combination therapies, and increasing implementation of biomarker-directed approaches. Recent randomized trials have shown that new therapeutic strategies significantly prolong progression-free survival in this setting, with some treatments reaching notable numerical improvements. Translating these options into routine clinical practice remains challenging due to heterogeneous trial designs, lack of head-to-head comparisons, suboptimal comparator treatments, and limited overall survival data. While the increasing implementation of biomarkers holds the potential for more personalized treatments, their clinical utility depends on their mechanistic and contextual biological relevance, methodological reliability of detection, and proven predictive value in clinical trials. Based on the current evidence, optimal treatment selection and sequencing in the post-CDK4\/6 inhibitor setting remain insufficiently defined, and optimization of biomarker-guided treatment requires further mechanistic understanding and methodological refinement. This narrative review provides an overview of the most recent randomized clinical trial evidence shaping current clinical practice and discusses persistent uncertainties regarding its implementation in routine care.<\/jats:p>","DOI":"10.37349\/etat.2026.1002400","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:54:29Z","timestamp":1789116869000},"update-policy":"https:\/\/doi.org\/10.37349\/open_exploration_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-CDK4\/6 inhibitor therapy in HR+\/HER2\u2013 advanced breast cancer: expanding options and persisting uncertainties"],"prefix":"10.37349","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4952-1697","authenticated-orcid":false,"given":"Anne-Murielle","family":"Hollinger","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4674-2531","authenticated-orcid":false,"given":"Ruben","family":"Bill","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21850","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast Cancer Treatment: A Review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.annonc.2025.10.005","article-title":"Overall survival with abemaciclib in early breast cancer","volume":"37","author":"Johnston","year":"2026","journal-title":"Ann Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/nejmoa1911149","article-title":"Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/s1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/nejmoa1810527","article-title":"Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/nejmoa2114663","article-title":"Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1200\/jco.23.00137","article-title":"Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer","volume":"42","author":"Slamon","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105858","article-title":"Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive\/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival","volume":"10","author":"Crown","year":"2025","journal-title":"ESMO Open"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","article-title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2\u2212 advanced breast cancer: final overall survival results of MONARCH 3","volume":"35","author":"Goetz","year":"2024","journal-title":"Ann Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.annonc.2025.07.017","article-title":"Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline","volume":"36","author":"Trapani","year":"2025","journal-title":"Ann Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.annonc.2026.05.707","article-title":"Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"37","author":"de Azambuja","year":"2026","journal-title":"Ann Oncol"},{"key":"ref14","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 4.2026 [Internet]. Plymouth Meeting (PA): National Comprehensive Cancer Network; c2026 [cited 2026 Jun 30]. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41568-023-00604-3","article-title":"Therapeutic resistance to anti-oestrogen therapy in breast cancer","volume":"23","author":"Will","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s43018-024-00893-z","article-title":"Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer","volume":"6","author":"Asciolla","year":"2025","journal-title":"Nat Cancer"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/jco.2018.78.9909","article-title":"Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor\u2013Positive, Human Epidermal Growth Factor Receptor 2\u2013Negative Advanced Breast Cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/jco.2017.73.7585","article-title":"MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+\/HER2\u2212 Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/nejmoa1609709","article-title":"Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/nejmoa1607303","article-title":"Palbociclib and Letrozole in Advanced Breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/nejmoa1505270","article-title":"Palbociclib in Hormone-Receptor\u2013Positive Advanced Breast Cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105758","article-title":"Managing relapses during or after adjuvant CDK4\/6 inhibitors in HR-positive\/HER2-negative early breast cancer: an emerging challenge","volume":"10","author":"Gerosa","year":"2025","journal-title":"ESMO Open"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1056\/nejmoa2501796","article-title":"Overall Survival with Inavolisib in","volume":"393","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104979","article-title":"408TiP INAVO123: Phase III study of first-line (1L) inavolisib\/placebo + a CDK4\/6 inhibitor + letrozole (INAVO\/PBO + CDK4\/6i + LET) in participants (pts) with PIK3CA-mutated (mut), hormone receptor-positive (HR+), HER2-negative (HER2\u2013), endocrine-sensitive advanced breast cancer (aBC)","volume":"10","author":"Cort\u00e9s","year":"2025","journal-title":"ESMO Open"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2021.39.15_suppl.tps1101","article-title":"SERENA-4: A phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease","volume":"39","author":"Im","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2021.39.15_suppl.tps1103","article-title":"persevERA Breast Cancer (BC): Phase III study evaluating the efficacy and safety of giredestrant (GDC-9545) + palbociclib versus letrozole + palbociclib in patients (pts) with estrogen-receptor-positive, HER2-negative locally advanced or metastatic BC (ER+\/HER2\u2013 LA\/mBC)","volume":"39","author":"Turner","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.sabcs25-ps5-12-18","article-title":"Abstract PS5-12-18: OPERA-02: a phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer","volume":"32","author":"Tolaney","year":"2026","journal-title":"Clin Cancer Res"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.1046","article-title":"624TiP Randomized phase 3 clinical trial evaluating atirmociclib plus letrozole versus a CDK4\/6 inhibitor plus letrozole as first-line treatment for patients with HR+\/HER2\u2212 advanced\/metastatic breast cancer","volume":"36","author":"Bidard","year":"2025","journal-title":"Ann Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"GS1","DOI":"10.1158\/1557-3265.sabcs25-gs1-10","article-title":"Abstract GS1-10: Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial","volume":"32","author":"Bardia","year":"2026","journal-title":"Clin Cancer Res"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102569","article-title":"Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?","volume":"117","author":"Corti","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast Cancer Res"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01290-x","article-title":"Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer","volume":"22","author":"Clatot","year":"2020","journal-title":"Breast Cancer Res"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/annonc\/mdx483","article-title":"Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer","volume":"29","author":"Fribbens","year":"2018","journal-title":"Ann Oncol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102432","article-title":"Accelerating drug development in breast cancer: New frontiers for ER inhibition","volume":"109","author":"Ferraro","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16244179","article-title":"Fulvestrant Monotherapy After CDK4\/6 Inhibitors in Metastatic Breast Cancer Patients: A Real-Life Experience","volume":"16","author":"Agostini","year":"2024","journal-title":"Cancers"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/oncolo\/oyac075","article-title":"Systemic Therapies Following Progression on First-line CDK4\/6-inhibitor Treatment: Analysis of Real-world Data","volume":"27","author":"Martin","year":"2022","journal-title":"Oncologist"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050884","article-title":"Efficiency of Fulvestrant Monotherapy After CDK4\/6 Inhibitor Exposure: Is This a Viable Choice?","volume":"17","author":"Ogata","year":"2025","journal-title":"Cancers"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/jco.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor\u2013Positive, Human Epidermal Growth Factor Receptor 2\u2013Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1200\/jco.23.02112","article-title":"US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor\u2013Positive, Human Epidermal Growth Factor Receptor 2\u2013Negative,","volume":"42","author":"Shah","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1158\/1078-0432.ccr-24-1073","article-title":"Elacestrant in ER+, HER2\u2212 Metastatic Breast Cancer with","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin Cancer Res"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/s1470-2045(24)00387-5","article-title":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial","volume":"25","author":"Oliveira","year":"2024","journal-title":"Lancet Oncol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1056\/nejmoa2502929","article-title":"First-Line Camizestrant for Emerging","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/nejmoa2410858","article-title":"Imlunestrant with or without Abemaciclib in Advanced Breast Cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.annonc.2025.11.018","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial","volume":"37","author":"Jhaveri","year":"2026","journal-title":"Ann Oncol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1200\/jco.22.02746","article-title":"AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor\u2013Positive, Human Epidermal Growth Factor Receptor 2\u2013Negative Advanced Breast Cancer","volume":"41","author":"Tolaney","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1200\/JCO.23.0150","article-title":"Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study","volume":"42","author":"Mart\u00edn","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"S1561","DOI":"10.1016\/j.annonc.2025.09.026","article-title":"LBA16 Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2\u2013 aBC) previously treated with a CDK4\/6 inhibitor (i): Primary results of the phase III evERA BC trial","volume":"36","author":"Mayer","year":"2025","journal-title":"Ann Oncol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.tps1130","article-title":"pionERA Breast Cancer (BC): Phase III study of first-line (1L) giredestrant vs. fulvestrant, both combined with a cyclin-dependent kinase 4\/6 inhibitor (CDK4\/6i), in patients (pts) with estrogen receptor-positive (ER+), HER2\u2013 locally advanced\/metastatic BC (LA\/mBC) with resistance to prior adjuvant (adj) endocrine therapy (ET)","volume":"42","author":"Kalinsky","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/nejmoa2505725","article-title":"Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer","volume":"393","author":"Campone","year":"2025","journal-title":"N Engl J Med"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.annonc.2023.09.3104","article-title":"Lasofoxifene versus fulvestrant for ER+\/HER2\u2212 metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial","volume":"34","author":"Goetz","year":"2023","journal-title":"Ann Oncol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/14796694.2025.2608863","article-title":"OPERA-01: a phase III study of palazestrant for ER+, HER2\u2013 advanced breast cancer after CDK4\/6 inhibitor therapy","volume":"22","author":"Pistilli","year":"2026","journal-title":"Future Oncol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1200\/jco-24-01865","article-title":"Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor\u2013Positive\/Human Epidermal Growth Factor Receptor 2\u2013Negative Advanced Breast Cancer: PALMIRA Trial","volume":"43","author":"Llombart-Cussac","year":"2025","journal-title":"J Clin Oncol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1200\/jco.23.01940","article-title":"PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4\/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor\u2013Positive\/Human Epidermal Growth Factor Receptor\u2013Negative Metastatic Breast Cancer","volume":"42","author":"Mayer","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.annonc.2025.11.002","article-title":"Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer","volume":"37","author":"Cabel","year":"2026","journal-title":"Ann Oncol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/jco.22.02392","article-title":"Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4\/6 Inhibition in Hormone Receptor\u2013Positive, Human Epidermal Growth Factor Receptor 2\u2013Negative Metastatic Breast Cancer: MAINTAIN Trial","volume":"41","author":"Kalinsky","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1200\/jco-24-02086","article-title":"Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4\/6 Inhibition: Results From the Phase III postMONARCH Trial","volume":"43","author":"Kalinsky","year":"2025","journal-title":"J Clin Oncol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.annonc.2023.09.3103","article-title":"Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+\/HER2\u2212 breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2","volume":"34","author":"Damodaran","year":"2023","journal-title":"Ann Oncol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1080\/14796694.2025.2481825","article-title":"ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+\/HER2-,","volume":"21","author":"Goetz","year":"2025","journal-title":"Future Oncol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102861","article-title":"PI3K\/AKT\/mTOR inhibitors for hormone receptor-positive advanced breast cancer","volume":"132","author":"Hao","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/s1470-2045(23)00676-9","article-title":"Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer","volume":"25","author":"Browne","year":"2024","journal-title":"Lancet Oncol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ctrv.2017.07.005","article-title":"Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients","volume":"59","author":"Janku","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1200\/jco.2017.76.9331","article-title":"Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor\u2013Positive, Human Epidermal Growth Factor Receptor 2\u2013Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102","volume":"36","author":"Kornblum","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1200\/jco.2011.39.0708","article-title":"Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor\u2013Positive, Human Epidermal Growth Factor Receptor 2\u2013Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study","volume":"30","author":"Bachelot","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/nejmoa1109653","article-title":"Everolimus in Postmenopausal Hormone-Receptor\u2013Positive Advanced Breast Cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/jco.2014.60.1971","article-title":"Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor\u2013Positive, Human Epidermal Growth Factor Receptor 2\u2013Negative Advanced Breast Cancer: Results From BOLERO-2","volume":"34","author":"Hortobagyi","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/bjc.2017.25","article-title":"Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2\u2212 advanced breast cancer: results from BOLERO-2","volume":"116","author":"Moynahan","year":"2017","journal-title":"Br J Cancer"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1158\/2159-8290.cd-20-1647","article-title":"Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative","volume":"11","author":"Aftimos","year":"2021","journal-title":"Cancer Discov"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1158\/2159-8290.cd-18-0264","article-title":"The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial","volume":"8","author":"O'Leary","year":"2018","journal-title":"Cancer Discov"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01284-9","article-title":"Frequency and spectrum of PIK3CA somatic mutations in breast cancer","volume":"22","author":"Mart\u00ednez-S\u00e1ez","year":"2020","journal-title":"Breast Cancer Res"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10549-023-07010-1","article-title":"Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysis","volume":"201","author":"Rosin","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/nejmoa1813904","article-title":"Alpelisib for","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","article-title":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2\u2013negative advanced breast cancer: final overall survival results from SOLAR-1","volume":"32","author":"Andr\u00e9","year":"2021","journal-title":"Ann Oncol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"e629","DOI":"10.1016\/s1470-2045(24)00673-9","article-title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study","volume":"25","author":"Rugo","year":"2024","journal-title":"Lancet Oncol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"RF7","DOI":"10.1158\/1557-3265.sabcs25-rf7-02","article-title":"Abstract RF7-02: Alpelisib plus fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer after a CDK4\/6 inhibitor (EPIK-B5): Phase III, randomized, double-blind, placebo-controlled, multicenter study","volume":"32","author":"De","year":"2026","journal-title":"Clin Cancer Res"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.tps1136","article-title":"INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2\u2013),","volume":"42","author":"Juric","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref81","unstructured":"Relay Therapeutics, Inc. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+\/HER2- Breast Cancer (ReDiscover-2) [Internet]. Bethesda (MD): National Library of Medicine (US); c2025 [cited 2026 Mar 14]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06982521"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/nejmoa2214131","article-title":"Capivasertib in Hormone Receptor\u2013Positive Advanced Breast Cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.sabcs23-po2-19-10","article-title":"Abstract PO2-19-10: CAPItello-292 Phase 3: An open-label, randomized study of capivasertib, fulvestrant, and investigator\u2019s choice of CDK4\/6 inhibitor (palbociclib or ribociclib) in HR+\/HER2\u2013 advanced breast cancer","volume":"84","author":"Rugo","year":"2024","journal-title":"Cancer Res"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.17_suppl.lba1005","article-title":"A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4\/6 inhibitor and aromatase inhibitor: The CCTG\/BCT MA.40\/FINER study (NCT04650581)","volume":"43","author":"Chia","year":"2025","journal-title":"J Clin Oncol"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.tps1129","article-title":"ADELA: A double-blind, placebo-controlled, randomized phase 3 trial of elacestrant (ELA) + everolimus (EVE) versus ELA + placebo (PBO) in ER+\/HER2- advanced breast cancer (aBC) patients with","volume":"43","author":"Llombart-Cussac","year":"2025","journal-title":"J Clin Oncol"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1200\/JCO-25-02643","article-title":"VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive\/HER2-\/PIK3CA Wild-Type Advanced Breast Cancer","volume":"44","author":"Hurvitz","year":"2026","journal-title":"J Clin Oncol"},{"key":"ref87","unstructured":"Drugs@FDA: FDA-Approved Drugs [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; c2026 [cited 2026 Jul 2]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm"},{"key":"ref88","unstructured":"Medicines [Internet]. Amsterdam: European Medicines Agency; c2026 [cited 2026 Jul 2]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann Oncol"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1200\/jco.20.02151","article-title":"TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","article-title":"Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial","volume":"31","author":"Litton","year":"2020","journal-title":"Ann Oncol"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1200\/JCO-25-02075","article-title":"TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2","volume":"44","author":"Tung","year":"2026","journal-title":"J Clin Oncol"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/nejmoa1802905","article-title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/oncolo\/oyad021","article-title":"Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline","volume":"28","author":"Savill","year":"2023","journal-title":"Oncologist"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10549-023-07165-x","article-title":"Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY","volume":"204","author":"Balma\u00f1a","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/nejmoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"S342","DOI":"10.1016\/j.annonc.2023.09.565","article-title":"388P Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician\u2019s choice (TPC)","volume":"34","author":"Tsurutani","year":"2023","journal-title":"Ann Oncol"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103699","article-title":"Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial","volume":"9","author":"Vaz","year":"2024","journal-title":"ESMO Open"},{"key":"ref101","unstructured":"DualityBio Inc. A Study of DB-1303\/BNT323 vs Investigator\u2019s Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) [Internet]. Bethesda (MD): National Library of Medicine (US); c2023 [cited 2026 Jul 21]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06018337"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"GS1","DOI":"10.1158\/1557-3265.sabcs25-gs1-09","article-title":"Abstract GS1-09: Sacituzumab govitecan vs chemotherapy as first therapy after endocrine therapy in HR+\/HER2\u2212 (IHC 0, 1+, 2+\/ISH\u2212) metastatic breast cancer: Primary results from ASCENT-07","volume":"32","author":"Jhaveri","year":"2026","journal-title":"Clin Cancer Res"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable\/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J Clin Oncol"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.annonc.2025.12.017","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study","volume":"37","author":"Pistilli","year":"2026","journal-title":"Ann Oncol"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.sabcs25-ps5-07-21","article-title":"Abstract PS5-07-21: TROPION-Breast06: Multicenter, multinational, open-label, single-arm, phase 3b study of datopotamab deruxtecan (Dato-DXd) in patients (pts) with locally advanced inoperable or metastatic HR+\/HER2 IHC 0 breast cancer (BC) refractory to endocrine therapy","volume":"32","author":"Jhaveri","year":"2026","journal-title":"Clin Cancer Res"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2025.100925","article-title":"International Expert Consensus Recommendations for HER2 Reporting in Breast Cancer: Focus on HER2-Low and Ultralow Categories","volume":"39","author":"Rakha","year":"2026","journal-title":"Mod Pathol"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172940","article-title":"Unlocking the Potential of Immune Checkpoint Inhibitors in HR+\/HER2\u2212 Breast Cancer: A Systematic Review","volume":"17","author":"Di","year":"2025","journal-title":"Cancers"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.tps1118","article-title":"KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+\/HER2- locally recurrent inoperable or metastatic breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.17_suppl.lba1004","article-title":"SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive\/HER2-negative breast cancer","volume":"42","author":"Garrido-Castro","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.sabcs24-p4-08-09","article-title":"Abstract P4-08-09: Phase 3, Randomized, Open-label TroFuse-010 Study of Sacituzumab Tirumotecan (sac-TMT) Alone & W\/ Pembrolizumab vs. Treatment of Physician\u2019s Choice Chemotherapy in Patients With HR+\/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer","volume":"31","author":"Tolaney","year":"2025","journal-title":"Clin Cancer Res"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00858-0","article-title":"Exploring KAT6 as a therapeutic target in breast cancer: epigenetic approaches for precision medicine","volume":"11","author":"Roussel-Simonin","year":"2025","journal-title":"npj Breast Cancer"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.1039","article-title":"617TiP Randomized phase 3 trial evaluating KAT6 inhibitor PF-07248144 plus fulvestrant in HR+HER\u2212 advanced\/metastatic breast cancer after progression on CDK4\/6 inhibitor-based therapy","volume":"36","author":"Oliveira","year":"2025","journal-title":"Ann Oncol"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41573-026-01431-5","article-title":"The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond","volume":"25","author":"Knudsen","year":"2026","journal-title":"Nat Rev Drug Discov"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.sabcs25-ps5-07-22","article-title":"Abstract PS5-07-22: Herthena-breast04: a phase 3, randomized, open-label study evaluating the efficacy and safety of patritumab deruxtecan (HER3-DXd) versus treatment of physician\u2019s choice in hormone receptor-positive (HR+)\/human epidermal growth factor receptor 2-negative (HER2\u2212) unresectable locally advanced or metastatic breast cancer","volume":"32","author":"Pistilli","year":"2026","journal-title":"Clin Cancer Res"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1200\/op-24-00547","article-title":"Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor\u2013Positive Breast Cancer: ASCO Guideline Clinical Insights","volume":"21","author":"Makhlin","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"ref116","unstructured":"Spezialit\u00e4tenliste [Specialities List] [Internet]. Bern: Bundesamt f\u00fcr Gesundheit; c2026 [cited 2026 Jul 3]. Available from: https:\/\/www.sl.bag.admin.ch\/sl"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105936","article-title":"Clinical management of common toxicities with inhibitors targeting the PI3K\/AKT\/mTOR pathway in breast cancer","volume":"11","author":"Jhaveri","year":"2026","journal-title":"ESMO Open"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10549-024-07376-w","article-title":"Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(\u2212) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice","volume":"207","author":"Bhave","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103731","article-title":"Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations","volume":"9","author":"Boscolo","year":"2024","journal-title":"ESMO Open"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43324-w","article-title":"Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer","volume":"14","author":"Tarantino","year":"2023","journal-title":"Nat Commun"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113371","article-title":"Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression","volume":"195","author":"Atallah","year":"2023","journal-title":"Eur J Cancer"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","article-title":"ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann Oncol"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1016\/j.celrep.2019.04.098","article-title":"The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer","volume":"27","author":"De","year":"2019","journal-title":"Cell Rep"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2025.104202","article-title":"Histopathological Insights into Metastatic Breast Cancer Gained From Rapid Autopsies","volume":"105","author":"Zels","year":"2025","journal-title":"Lab Investig"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejca.2023.04.026","article-title":"Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer","volume":"188","author":"Geukens","year":"2023","journal-title":"Eur J Cancer"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2023.100002","article-title":"Liquid biopsy: Cell-free DNA based analysis in breast cancer","volume":"1","author":"Venetis","year":"2023","journal-title":"J Liq Biopsy"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/s41416-021-01601-9","article-title":"Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients","volume":"126","author":"Suppan","year":"2022","journal-title":"Br J Cancer"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1158\/1078-0432.ccr-11-2696","article-title":"Detection of Tumor","volume":"18","author":"Higgins","year":"2012","journal-title":"Clin Cancer Res"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.51700","article-title":"Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort","volume":"7","author":"Iams","year":"2024","journal-title":"JAMA Netw Open"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1158\/1078-0432.ccr-22-2115","article-title":"Biology and Targetability of the Extended Spectrum of","volume":"29","author":"Rugo","year":"2023","journal-title":"Clin Cancer Res"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102642","article-title":"ESR1 mutations in HR+\/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing","volume":"121","author":"Venetis","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/s1470-2045(19)30817-4","article-title":"Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial","volume":"21","author":"Jones","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/s1470-2045(22)00284-4","article-title":"Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial","volume":"23","author":"Howell","year":"2022","journal-title":"Lancet Oncol"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.sabcs23-po2-20-02","article-title":"Abstract PO2-20-02: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+\/HER2- advanced breast cancer previously treated with a CDK4\/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)","volume":"84","author":"Hurvitz","year":"2024","journal-title":"Cancer Res"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/nejmoa2115022","article-title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1200\/JCO.24.00248","article-title":"Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update","volume":"42","author":"Burstein","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1200\/jco.23.00638","article-title":"Testing for","volume":"41","author":"Burstein","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/jco.22.02864","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO\u2013College of American Pathologists Guideline Update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref139","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.sabcs25-ps5-07-18","article-title":"Abstract PS5-07-18: Advancing personalized treatment of patients with metastatic breast cancer by functional drug screening and IMC profiling","volume":"32","author":"Vetter","year":"2026","journal-title":"Clin Cancer Res"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ccell.2025.11.003","article-title":"Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+\/HER2\u2212 breast cancer: The LINUXtrial","volume":"44","author":"Fan","year":"2026","journal-title":"Cancer Cell"},{"key":"ref142","unstructured":"Orserdu: EPAR - Product information [Internet]. Amsterdam: European Medicines Agency; c2023 [cited 2026 Jun 1]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/orserdu-epar-product-information_en.pdf"},{"key":"ref143","unstructured":"Stemline Therapeutics, Inc. Orserdu: Full prescribing information [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; c2023 [cited 2026 Jun 1]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/217639Orig1s001correctedlbl.pdf"},{"key":"ref144","unstructured":"Inluriyo: EPAR - Product information [Internet]. Amsterdam: European Medicines Agency; c2026 [cited 2026 Jun 1]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/inluriyo-epar-product-information_en.pdf"},{"key":"ref145","unstructured":"Eli Lilly and Company. Inluriyo: Full prescribing information [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; c2025 [cited 2026 Jun 1]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/218881s000lbl.pdf"},{"key":"ref146","unstructured":"Veppanu: NDA Approval [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; c2026 [cited 2026 Jun 1]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2026\/219835Orig1s000ltr.pdf"}],"container-title":["Exploration of Targeted Anti-tumor Therapy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:54:36Z","timestamp":1789116876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.explorationpub.com\/Journals\/etat\/Article\/1002400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":146,"URL":"https:\/\/doi.org\/10.37349\/etat.2026.1002400","archive":["Portico","Portico"],"relation":{},"ISSN":["2692-3114"],"issn-type":[{"value":"2692-3114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"2026-03-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-11","order":2,"name":"published","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1002400"}}